{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:40:07Z","timestamp":1773056407042,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T00:00:00Z","timestamp":1610668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We have performed a head to head comparison of all-oral triplet combination of ixazomib, lenalidomide and dexamethasone (IRD) versus lenalidomide and dexamethasone (RD) in patients with relapsed and refractory multiple myeloma (RRMM) in the routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 344 patients treated with IRD (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009127) or RD (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009217) were selected for analysis from the Czech Registry of Monoclonal Gammopathies (RMG). Descriptive statistics were used to assess patient\u2019s characteristics associated with the respective therapy. The primary endpoint was progression free survival (PFS), secondary end points included response rates and overall survival (OS). Survival endpoints were plotted using Kaplan-Meier methodology at 95% Greenwood confidence interval. Univariable and multivariable Cox proportional hazards models were used to evaluate the effect of treatment regimens and the significance of uneven variables. Statistical tests were performed at significance level 0.05.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the whole cohort, median PFS for IRD was 17.5 and for RD was 11.5\u2009months favoring the all-oral triplet,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005; in patients within relapse 1\u20133, the median PFS was 23.1 vs 11.6\u2009months,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001. The hazard ratio for PFS was 0.67 (95% confidence interval [CI] 0.51\u20130.89,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). The PFS advantage translated into improved OS for patients treated with IRD, median 36.6\u2009months vs 26.0\u2009months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008). The overall response rate (ORR) was 73.0% in the IRD group vs 66.2% in the RD group with a complete response rate (CR) of 11.1% vs 8.8%, and very good partial response (VGPR) 22.2% vs 13.9%, IRD vs RD respectively. The IRD regimen was most beneficial in patients \u226475\u2009years with ISS I, II, and in the first and second relapse. Patients with the presence of extramedullary disease did not benefit from IRD treatment (median PFS 6.5\u2009months). Both regimens were well tolerated, and the incidence of total as well as grade 3\/4 toxicities was comparable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our analysis confirms the results of the TOURMALINE-MM1 study and shows benefit of all-oral triplet IRD treatment versus RD doublet. It demonstrates that the addition of ixazomib to RD improves key survival endpoints in patients with RRMM in a routine clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-07732-1","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:03:17Z","timestamp":1610715797000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0513-326X","authenticated-orcid":false,"given":"Jiri","family":"Minarik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Pika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Radocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Jungova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Straub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludek","family":"Pour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Pavlicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Mistrik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Brozova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Krhovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Machalkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hana","family":"Plonkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaroslav","family":"Bacovsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Capkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal","family":"Sykora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Kessler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Stejskal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Heindorfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana","family":"Ullrychova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Skacel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"issue":"17","key":"7732_CR1","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"key":"7732_CR2","doi-asserted-by":"publisher","unstructured":"Leleu X, Masszi T, Bahlis NJ, et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am J Hematol. 2018. https:\/\/doi.org\/10.1002\/ajh.25134.","DOI":"10.1002\/ajh.25134"},{"issue":"13","key":"7732_CR3","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15(13):1503\u201312.","journal-title":"Lancet Oncol"},{"issue":"20","key":"7732_CR4","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1182\/blood-2016-05-717769","volume":"128","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, LaPlant BR, Reeder CB, et al. Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib. Blood. 2016;128(20):2415\u201322.","journal-title":"Blood."},{"issue":"4","key":"7732_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.14733","volume":"178","author":"S Kumar","year":"2017","unstructured":"Kumar S, Moreau P, Hari P, et al. Management of adverse events associated with ixazomib plus lenalidomide\/dexamethasone in relapsed\/refractory multiple myeloma. Br J Haematol. 2017;178(4):571\u201382.","journal-title":"Br J Haematol"},{"issue":"24","key":"7732_CR6","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood. 2017;130(24):2610\u20138.","journal-title":"Blood."},{"issue":"10","key":"7732_CR7","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","volume":"102","author":"MV Mateos","year":"2017","unstructured":"Mateos MV, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102(10):1767\u201375.","journal-title":"Haematologica."},{"key":"7732_CR8","unstructured":"Millennium Pharmaceuticals Inc. NINLARO (ixazomib) capsules for oral use. United States Prescribing Information. 2016. https:\/\/www.ninlaro.com\/prescribing-information.pdf. Accessed 12 Feb 2019."},{"issue":"11","key":"7732_CR9","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41408-018-0141-0","volume":"8","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109.","journal-title":"Blood Cancer J"},{"issue":"12","key":"7732_CR10","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.3109\/10428194.2016.1170828","volume":"57","author":"LJ Costa","year":"2016","unstructured":"Costa LJ, Hari PN, Kumar SK. Differences between unselected patients and participants in multiple myeloma clinical trials in US: a threat to external validity. Leuk Lymphoma. 2016;57(12):2827\u201332.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"7732_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1365-2141.2012.09233.x","volume":"159","author":"J Minarik","year":"2012","unstructured":"Minarik J, Pika T, Bacovsky J, Langova K, Scudla V. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients. Br J Haematol. 2012;159(1):111\u20133.","journal-title":"Br J Haematol"},{"issue":"2","key":"7732_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","volume":"9","author":"L Pour","year":"2009","unstructured":"Pour L, Adam Z, Buresova L, et al. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma. 2009;9(2):151\u20133.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"5","key":"7732_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102(5):1115\u201323.","journal-title":"Br J Haematol"},{"issue":"18","key":"7732_CR14","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117(18):4691\u20135.","journal-title":"Blood."},{"issue":"9","key":"7732_CR15","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467\u201373.","journal-title":"Leukemia."},{"issue":"23","key":"7732_CR16","doi-asserted-by":"publisher","first-page":"4514","DOI":"10.1182\/blood.V126.23.4514.4514","volume":"126","author":"J Radocha","year":"2015","unstructured":"Radocha J, Pour L, Spicka I, et al. Registry of monoclonal Gammopathies (RMG) in the Czech Republic. Blood. 2015;126(23):4514.","journal-title":"Blood."},{"issue":"Supplement 1","key":"7732_CR17","first-page":"3087","volume":"130","author":"E Terpos","year":"2017","unstructured":"Terpos E, Maouche N, Minarik J, et al. \u201cReal world\u201d data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a combined study from the Greek, Czech and UK Databases. Blood. 2017;130(Supplement 1):3087.","journal-title":"Blood"},{"issue":"4","key":"7732_CR18","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s12253-019-00607-2","volume":"25","author":"G Varga","year":"2019","unstructured":"Varga G, Nagy Z, Demeter J, et al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed\/refractory multiple myeloma: data collected from the Hungarian ixazomib named patient program. Pathol Oncol Res. 2019;25(4):1615\u201320.","journal-title":"Pathol Oncol Res"},{"issue":"Supplement 1","key":"7732_CR19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1182\/blood-2018-99-113441","volume":"132","author":"R Hajek","year":"2018","unstructured":"Hajek R, Terpos E, Lee HC, et al. Ixazomib plus lenalidomide-dexamethasone (IRd) in relapsed\/refractory multiple myeloma (MM) patients (Pts) - effectiveness in routine clinical practice is similar to the efficacy in the phase 3 tourmaline-MM1 trial: a pooled analysis from the insight MM observational study and the Czech registry of monoclonal gammopathies (RMG). Blood. 2018;132(Supplement 1):1971.","journal-title":"Blood"},{"issue":"Supplement 1","key":"7732_CR20","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood-2018-99-112046","volume":"132","author":"J Minarik","year":"2018","unstructured":"Minarik J, Krhovska P, Jelinek T, et al. Treatment of relapsed and refractory multiple myeloma with fully oral triplet IRD (ixazomib, lenalidomide and dexamethasone) is safe and with significant therapeutic outcomes. Blood. 2018;132(Supplement 1):1959.","journal-title":"Blood"},{"issue":"12","key":"7732_CR21","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","volume":"35","author":"CHY van Beurden-Tan","year":"2017","unstructured":"van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma. J Clin Oncol. 2017;35(12):1312\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"7732_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood-2013-07-517276","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Xie W, Jagannath S, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed\/refractory myeloma. Blood. 2014;123(10):1461\u20139.","journal-title":"Blood."},{"issue":"2","key":"7732_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"8","key":"7732_CR24","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel DS, Dimopoulos MA, Ludwig H, et al. Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(8):728\u201334.","journal-title":"J Clin Oncol"},{"issue":"7","key":"7732_CR25","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"7732_CR26","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","volume":"103","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088\u201396.","journal-title":"Haematologica."},{"issue":"14","key":"7732_CR27","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"7732_CR28","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1182\/blood-2018-99-112697","volume":"132","author":"N Bahlis","year":"2018","unstructured":"Bahlis N, Dimopoulos MA, White DJ, et al. Three-year follow up of the phase 3 pollux study of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in relapsed or refractory multiple myeloma (RRMM). Blood. 2018;132(Supplement 1):1996.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07732-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07732-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T13:04:09Z","timestamp":1610715849000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07732-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,15]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7732"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07732-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-45379\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-45379\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-45379\/v2","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,15]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the patients provided written, informed consent prior to participation in the program, and the study was performed under the control of the state regulatory office (SUKL \u2013 Statni Ustav pro Kontrolu Leciv); the collection of data in RMG and their assessment was approved by local ethical committees at each participating site:Ethical Committee of University Hospital Olomouc, Ethical Committee - Faculty Hospital Hradec Kralove, Local Ethical Committee of University Hospital Pilsen, Ethical Committee of General Faculty Hospital Prague, Ethical Committee of University Hospital Ostrava, Ethical Committee of University Hospital Brno, Ethical Committee of Faculty Hospital Kralovske Vinohrady, Ethical Committee of University Hospital Bratislava, Ethical Committee of Hospital Ceske Budejovice, Ethical Committee of Hospital Pelhrimov, Ethical Committee of Silesian Hospital in Opava, Ethical Committee of Hospital Liberec, Ethical Committee of Masaryk Hospital in Usti nad Labem,","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM received honoraria from Amgen, Takeda, Celgene, Janssen, BMS. JR received honoraria from Amgen and MSD. TJ received personal fees from: Amgen, Takeda, Celgene, Janssen, Karyopharm. IS received honoraria from Celgene, Amgen, Janssen-Cilag, Takeda, BMS, Novartis, Sanofi, VM had consultancy and received honoraria from Janssen, Amgen, Celgene, Takeda, participated on advisory boards: Janssen, Amgen, Celgene, BMS, Takeda, JS received honoraria from Celgene, Amgen, Takeda, Jannsen, BMS.LC and LB declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}